Nasonov_E.L._Антифосфолипидный синдром_(Literra,2004)-1

lowering effects the relevance of endothelial nitric oxide synthase and superoxide anion cavenging action. Atherosclerosis 2001; 155: 347—57.

53.Wilson SH, Simari RD, Best PJ, et al. Simvastatin preserves coronary endothelial func tion in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 2001; 21: 122—8.

54.Romano M, Mezzetti A, Marulli C, et al. Fluvastatin reduces soluble P selectin and ICAM 1 levels in hypercholesterolemic patients: role of nitric oxide. J Investig Med 2000; 48: 183—9.

55.Corsini A, Pazzucconi F, Arnaboldi L, et al. Direct effects of statins on the vascular wall. J Cardiovasc Pharmacol 1998; 31: 773—8.

56.Soma MR, Donetti E, Parolini C, et al. HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rab bits. Arterioscler Thromb 1993; 13: 571—578.

57.Yasunari K, Maeda K, Minami M, Yoshi kawa J. HMG CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress. Arterioscler Thromb Vasc Biol 2001; 21: 937—942.

58.Kwak B, Mulhaupt F, Myit S, Mach F. Sta tins as a newly recognized type of immunomodu lator. Nat Med 2000 Dec; 6: 1399—1402.

59.Steimle V, Siegrist CA, Mottet A, Lisowska Grospierre B, Mach B. Regulation of MHC class II expression by interferon gamma mediated by the transactivator gene CIITA. Science 1994; 265: 106—109.

60.Palinski W. Immunomodulation: a new role for statins? Nature Med 2000; 12: 1311—2.

61.Rosenson RS, Tangney CC, Casey LC. In hibition of proinflammatory cytokine production by pravastatin. Lancet 1999; 353: 983—4.

62.Grip O, Janciauskiene S, Lindgren S. Pra vastatin down regulates inflammatory mediators in human monocytes in vitro. Eur J Pharmacol 2000; 410: 83—92.

63.Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A: Anti inflammatory effects of simvastatin in subjects with hypercholes terolemia. Int J Cardiol. 2001; 77: 247—53.

64.Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, et al. The HMG Co A reductase inhibitor, ator vastatin, promotes a Th2 bias and reverses paral

ysis in central nervous system autoimmune dis ease. Nature 2002; 420: 78—84.

65.Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621—7.

66.Wenke K, Meiser B, Thiery J, et al. Simva statin reduces graft vessel disease and mortality after heart transplantation: a four year random ized trial. Circulation 1997; 96: 1398—402.

67.Bustos C, Hernandez Presa MA, Ortego M. et al. HMG CoA reductase inhibition by atorvas tatin redues neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998;

32:2057—64.

68.Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H, Madhok R, Campbel C, Gracie JA, Liew FY, McInnes IB. A novel anti inflammatory tole for simvastatin in inflammatory atthritis. J Immunol 2003; 170: 1524—1530.

69.Kanda H, Hamasaki K, Kubo K, et al. Antiinflammatory effect of simvastatin in patients with rheumatoid arthritis. J Rheumatology 2003;

70.Ridker PM, Rifai N, Pfeffer MA, et al. In flammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recur rent Events (CARE) Investigators. Circulation 1998; 98: 839—44.

71.Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long term effects of pravastatin on plasma concentration of C reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230—5.

72.Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C reactive protein with cerivastatin among 785 patients with primary hypercholes terolemia. Circulation 2001; 103: 1191—3.

73.Ridker PM, Rifai N, Cleatfield M, et al. For the Air Force/Texas Coronary Athrerosclerosis Prevention of acute coronary evenrs. N Engl J Med 2001; 344: 1959—1965.

74.Albett MA, Danielson E, Rifai N, Ridker PM. for the PRINCE Investigators. Effect of statin therapy on C reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64—70.

75.Jialal I, Stein D, Balis D. Effect of hydrox ymethyl glutaryl coenzyme A reductase inhibitor

therapy on high sensitive C reactive protein lev els. Circulation 2001; 103: 1933—1935.

76.Weber C, Erl W, Weber PC. Lovastatin induces differentiation of Mono Mac 6 cells. Cell Biochem Funct 1995; 13: 273—277.

77.Niwa S, Totsuka T, Hayashi S. Inhibitory effect of fluvastatin, an HMG CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immuno pharm 1996; 18: 669—675.

78.Wilson SH, Simari RD, Best PJ, et al. Simvastatin preserves coronary endothelial func tion in hypercholesterinemia in the absence of lipid lowering. Atheroscler Thromb Vasc Biol 2001; 21: 122—128.

79.Katoh M, Kurosawa Y, Tanaka K, et al. Fluvastatin inhibits O2 and ICAM 1 levels in a rat model with aortic remodeling induced by pres sure overload. Am J Physiol Heart Circ Physiol 2001; 281: H655—660.

80.Tanaka K, Yasuhara M, Suzumura K, et al. Effects of fluvastatin and its major metabolites on low density lipoprotein oxidation and cholesterol esterification in macrophages. Jpn J Pharmacol 2001; 86: 289—296.

81.Shiomi M, Ito T. Effect of cerivastatin sodi um, a new inhibotor of HMG CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits. Br J Pharmacol 1999; 126: 961—968.

82.Aikawa M, Rabkin E, Sugiyama S, et al. An HMG CoA reductase inhibitors, cerivas tatin, suppress growth of macrophages express ing matrix metalloproteinase and tissue factor in vivo and in vitro. Circulation 2001; 103: 276— 283.

83.Bellosta S, Via D, Canaveis M, et al. HMG CoA reductase inhibitors reduce MMP 9 secre tion by macrophages. Arteriol Thromb Vasc Biol 1998; 18: 1671—1678.

84.Buemi M, Allegra A, Senatore M, et al. Pro apoptotic effect of fluvastatin on human smooth mus cle cells. Eur J Pharmacol 1999; 370: 201—203.

85.Cutts JL, Bankhurst AD. Suppression of lymphoid cell function in vitro by inhibition of 3 hydroxy 3 methylglutaryl coenzyme A reductase by lovastatin. Int J Immunopharmacol 1989; 11: 863—869.

86.Cipollone F, Mezzetti A, Porreca E, et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia. Effect of statin therapy. Circulation 2003; 106: 399—402. Circulation 2002; 106: 399—402.

87.Rezai Majd A, Maca T, Bucek RA, et al. Simvastatin reduces expression of cytokines inter leukin 6, interleukin 8, and monocyte chemoat tractant protein 1 in circulating monocytes from hypercholesterolemic patients. Arteriol Thromb Vasc Biol 2002; 22: 1194—1199.

88.Насонов ЕЛ. Перспективы применения статинов в ревматологии. РМЖ, 2003; 23: 1273—1276.

89.Насонов ЕЛ. Патогенетическое и кли ническое обоснование применения статинов при системной красной волчанке и антифос фолипидном синдроме. Клин. фарм. Терапия, 2004; 13: 1—8.

90.Roubey RAS. New approaches to prevention of thrombosis in the antiphospholipid syndrome: hopes, trials, and tribulations. Arthritis Rheum 2003; 48: 3004—3008.

91.Weber C, Erl W, Weber KS, Weber PC. HMG CoA reductase inhibitors decrease CD11b expression and CD11b dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes to endothelium and reduce increased adhevsiveness of monocytes iso lated from patients with hypercholesterinemia. J Am Col Cardiol 1997; 30: 1212—1227.

92.Weitz Schmidt G, Welzenbach K, Brink mann V, et al. Statins selectively inhibit leukocyte function antigen 1 by binding to a novel regulato ry integrin site. Nat Med 2001;7:687—692.

93.Frenette PS. Lockin a leukocyte integrin with stastin. New Engl J Med 2001; 345: 1419— 1421.

94.Meroni PL, Raschi E, Testoni C, et al. Sta tins prevent endothelial cell activation induced by antiphospholipid (anti beta2 glycoprotein 1) antibodies. Effect on the proadhesive and proun flammatory phenotype. Arthritis Rheum 2001; 44: 2870—2878.

95.Ferrara D, Liu X, Espinola RG, et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibody by fluvas tatin in an in vivo model. Arthritis Rheum 2003;

48:3272—3279.